Researchers sought to assess whether COVID-19 infection developed despite of vaccination among patients with multiple sclerosis or neuromyelitis optica spectrum disorder, using a French database of these patient populations.
Presenting at CMSC 2021, researchers analyzed the long-term safety of satralizumab, a humanized monoclonal antibody, in patients with neuromyelitis optica spectrum disorder from the SAkura trials.
In a post-hoc descriptive analysis, researchers described the efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder who had previously received rituximab, a monoclonal antibody, in the PREVENT trial.
Researchers sought to compare the frequency, racial differences, neurologic phenotype, and outcome of attacks that required ventilator support in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Optic nerve enhancement patterns and white matter lesion distribution can guide diagnoses.
Study researchers sought to assess the effects of pregnancy on relapse pattern in patients with neuromyelitis optica spectrum disorder.
Investigators strove to quantify imaging patterns of central nervous system damage in MOGAD during the remission stage, and to compare it with NMOSD-AQP4 and MS.
Thalamic ventral posterior nucleus volume is associated with neuropathic pain intensity in patients with neuromyelitis optica spectrum disorders.
The terminal complement inhibitor eculizumab reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).
Patients with neuromyelitis optica spectrum disorder who experience relapses use more pain medication than non-relapsing patients.
